A little pre-weekend treat, just for you: A complimentary look at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:
-
Delta Air Lines (DAL) gets an upgrade on earnings beat news
- Why Zymeworks (ZYME) could deliver double-digit gains in the coming year
-
Ibex (IBEX) is our latest Stock of the Week — find out why
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
Buffett's $114 Secret
In 1943, a teenage Warren Buffett put $114 into a special type of account called "The 29% Account."
Today, that single, $114 investment would be worth over $15 million.
Your bank never told you about this.
Click Here to See How It Works
1. Delta Air Lines (NYSE: DAL)
A veritable industry giant, Delta is one of the largest airlines in the United States. The company delivered a solid beat in Q3 2025 — as a result, Wall Street analysts have gone on a barrage of price target hikes. The best part? DAL is incredibly cheap right now — but it might not stay that way for long.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $57.48 — get current quote >
Max 1-year forecast: $90.00
Why we’re watching:
- DAL enjoys broad, bullish support from Wall Street equity researchers — the stock currently has 9 Strong Buy ratings and 2 Buy ratings. See the ratings
- The average 12-month price forecast for Delta Air Lines shares currently stands at $73.91, and implies a hefty 28.58% upside.
- Raymond James’s Savanthi Syth (a top 12% rated analyst) doubled down on a Strong Buy rating on the stock following the company’s Q3 2025 earnings and hiked her price target from $68 to $70.
- According to Syth, "momentum in domestic main cabin improvement and continued overall premium strength" helped the company kick off Q3 earnings season with a beat and raise.
- The analyst said that Delta Air Lines has structural advantages over its older peers.
-
Thomas Wadewitz of UBS also reiterated a Strong Buy rating, and increased his price forecast from $72 to $75.
- Looking ahead, Wadewitz told readers that stock price upside is supported by improving sales and management's positive Q4 guidance.
- Delta Air Lines is the 2nd highest-rated stock in the Airline industry, which has an Industry Rating of B.
- DAL has a Zen Rating of B, and currently ranks in the top 7% of the equities that we track.
- Per its Artificial Intelligence Component Grade rating, Delta Air Lines ranks in the top 10% of stocks.
- When it comes to Value, DAL ranks in the 91st percentile, as the stock is trading at a price-to-earnings (P/E) ratio of just 8.05x.
-
Lastly, we have Sentiment, a category in which Delta Air Lines ranks in the top 8%, owing to the fact that 12% of the insider transactions tied to the stock in the past 12 months have been purchases. (See all 7 Zen Component Grades here >)

Zymeworks is a clinical-stage biopharmaceutical company focused on improving the efficacy and safety of cancer treatments. The company develops programs both in-house and through partnerships with major pharma players — so it enjoys a broad and diverse pipeline. However, the main draw here is quite specific — and it has to do with the smart money crowd.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $18.06 — get current quote >
Max 1-year forecast: $30.00
Why we’re watching:
- Zymeworks stock currently has 2 Strong Buy ratings and 1 Hold rating from Wall Street analysts. See the ratings
- With that being said, the average price target for ZYME shares, currently at $21.67, implies a hefty 19.97% upside, and paints a much more bullish picture.
-
Mayank Mamtani of B. Riley Securities (a top 4% rated analyst) recently initiated coverage on the stock with a Strong Buy rating and a Street-high $30 price target.
- The other Strong Buy rating comes from Citigroup’s Yigal Nochomovitz (a top 9% rated analyst), who set a $22 price target on the stock.
- ZYME ranks in the top 5% of the stocks that we track, giving it a Zen Rating of A, which has historically corresponded to an average annual return of 32.52%.
- In terms of its Growth Component Grade rating, Zymeworks ranks in the 96th percentile of equities.
- However, the stock’s most pronounced Component Grade rating is Sentiment — where it ranks in the top 1%. That might have something to do with the fact that a whopping 98.19% of the insider transactions tied to the stock in the past 12 months have been purchases. (See all 7 Zen Component Grades here >)

Ibex is an up-and-coming customer experience outsourcer that serves a variety of industries. It’s also our Stock of the Week. IBEX had a strong rally after a recent earnings beat, but has since gone down to a bargain price — and our Editor-in-Chief believes the stock could see prices increase by 35% by the end of the year if the company manages to extend its already impressive earnings beat streak.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $36.84 — get current quote >
Max 1-year forecast: $39.00
Why we’re watching:
- IBEX is our Stock of the Week. Our Editor-in-Chief, Steve Reitmeister, explained why he added it to his exclusive 20-stock strong Zen Investor portfolio in a Monday article.
- At the moment, large caps are, generally speaking, quite overvalued — in contrast, small-cap stocks like Ibex tend to have more upside potential
- The stock has a Zen Rating of A, and is actually ranked 3rd overall out of the roughly 4,600 equities that we track.
- After a recent earnings beat, IBEX shares rocketed up to $43 — having since receded back down to the mid $30’s, now is an opportune time to Buy the Dip.
- If the beat and raise cycle continues, our Editor-in-Chief believes that IBEX could reach prices as high as $50 by the end of the year, and possibly double its current price by the end of 2026.
- IBEX has some pretty compelling scores in terms of its Component Grade ratings. The stock ranks in the top 25% for Growth and the top 22% for Safety.
- In addition, Ibex shares rank in the top 10% with regard to the Momentum Component Grade rating.
- IBEX is also the top-rated stock in the Information Technology Service industry, which has an Industry Rating of B.
- Despite being a relatively low-profile stock, IBEX has attracted attention from the Smart Money crowd, as it ranks in the top 7% when it comes to Sentiment.
- Ibex stock is currently trading at an attractive P/E ratio of 14.68x and an even more attractive PEG ratio of just 0.56x — so it’s little wonder that it ranks in the 97th percentile according to Value.
-
Last, but certainly not least is the company’s impressive balance sheet — which has placed IBEX in the top 1% of stocks in terms of Financials. (See all 7 Zen Component Grades here >)

What to Do Next?